Day: November 21, 2022

Franco, Mauricio P. published the artcileEvaluation of N-binding through N1, N2 or N3 of 4-R-1,2,3-Triazolate to [CuCO]⁺ Complexes, Product Details of C2H2N4O2, the publication is ChemistrySelect (2022), 7(10), e202104006, database is CAplus.

We computationally investigated eight 4-R-1,2,3-triazolates and their three possible N-binding modes. Optimization of the pre-ligands to verify NPA charges were done with M06-2X/def2-TZVPP. The complexes with [CuCO]⁺ were optimized with M06 L/def2-TZVPP and the electronic energies were improved with DLPNO-CCSD(T)/cc-pVTZ. Our calculations with pre-ligands indicated the NPA charge of N2 as less neg. than N1 and N3 by at least ∼0.100 e. Taking into account the complexes energies and vibrations, coordination via N2 is the most stable among all three nitrogens in gas-phase by at least, 8 kJ/mol and the vibrational anal. of the ν_CO indicates linkage isomer N2 as the best electron d. donor among the three linkage isomers. The results exhibit a fine-tuning of ligand donation properties that can be achieved by selecting different R groups in 4-R-1,2,3-triazoles.

ChemistrySelect published new progress about 14544-45-7. 14544-45-7 belongs to triazoles, auxiliary class Triazoles, name is 5-Nitro-1H-1,2,3-triazole, and the molecular formula is C2H2N4O2, Product Details of C2H2N4O2.

Referemce:
https://en.wikipedia.org/wiki/1,2,3-Triazole,
Triazoles – an overview | ScienceDirect Topics

Chen, Jing-Lin published the artcileSynthesis, Characterization, and Photophysical Properties of Heteroleptic Copper(I) Complexes with Functionalized 3-(2′-Pyridyl)-1,2,4-triazole Chelating Ligands, Computed Properties of 219508-27-7, the publication is Inorganic Chemistry (2013), 52(17), 9727-9740, database is CAplus and MEDLINE.

Mononuclear Cu(I) complexes (1–9) with functionalized 3-(2′-pyridyl)-1,2,4-triazole chelating ligands, as well as the halide and/or phosphine ancillary ligands, were synthesized. Complexes 1–9 were fully characterized by elemental anal., NMR spectroscopy, mass spectroscopy, electronic absorption spectroscopy, fluorescence spectroscopy, cyclic voltammetry, and x-ray crystallog. (1–8). They adopt a distorted tetrahedral configuration, and are considerably air-stable in solid state and in solution All these Cu(I) complexes display a comparatively weak low-energy absorption in CH₂Cl₂ solution, assigned to charge-transfer transitions with appreciable MLCT character, as supported by TD-DFT studies. Cu(I) halide complexes 1–4 each shows bright solid-state emission at room temperature, though they are nonemissive in fluid solutions, in which emission markedly depends on the halide and the substituent on the 2-pyridyl ring. Complexes 5–9 bearing 2-pyridyl functionalized 1,2,4-triazole and phosphine exhibit good photoluminescence properties in solution and solid states at ambient temperature, which are well-modulated via the alteration of the auxiliary phosphine ligand and the structural modification of 3-(2′-pyridyl)-1,2,4-triazole. Cationic complex 6 and neutral derivative 7 can readily be interconverted through the ring inversion of the 1,2,4-triazolyl regulated by the NH ↔ N^– transformation.

Inorganic Chemistry published new progress about 219508-27-7. 219508-27-7 belongs to triazoles, auxiliary class Trifluoromethylated Building Blocks, name is 2-[5-(Trifluoromethyl)-1H-1,2,4-triazol-3-yl]pyridine, and the molecular formula is C8H5F3N4, Computed Properties of 219508-27-7.

Referemce:
https://en.wikipedia.org/wiki/1,2,3-Triazole,
Triazoles – an overview | ScienceDirect Topics

Hauser, Robert A. published the artcilePreladenant in patients with Parkinson’s disease and motor fluctuations: a phase 2, double-blind, randomised trial, Application In Synthesis of 377727-87-2, the publication is Lancet Neurology (2011), 10(3), 221-229, database is CAplus and MEDLINE.

Preladenant is an adenosine 2A (A_2A) receptor antagonist. In animal models of Parkinson’s disease, preladenant monotherapy improves motor function without causing dyskinesia and, as an adjunct to levodopa, it improves motor function without worsening dyskinesia. We aimed to assess the efficacy and safety of preladenant in patients with Parkinson’s disease and motor fluctuations who were receiving levodopa and other antiparkinsonian drugs. In this phase 2, dose-finding trial, patients with Parkinson’s disease who were receiving levodopa were enrolled and treated at 44 sites in 15 countries between Dec., 2006, and Nov., 2008. Assignment to treatment was done centrally with an interactive voice response system, according to a block randomisation schedule that was computer generated by the sponsor. Patients were assigned to receive 1, 2, 5, or 10 mg oral preladenant twice daily, or matching placebo for 12 wk. Patients, study staff, investigators, and all sponsor personnel were masked to treatment assignment. The primary outcome was change in mean daily off time from baseline to week 12, as assessed by home diaries. Efficacy anal. included all patients who received at least one dose of study drug and had data for assessments after baseline. This trial is registered with ClinicalTrials.gov, number NCT00406029. 253 Patients were randomised to receive preladenant (1 mg [n = 49], 2 mg [n = 49], 5 mg [n = 49], 10 mg [n = 57]) or placebo (n = 49), of whom 234 on preladenant (1 mg [n = 47], 2 mg [n = 48], 5 mg [n = 45], 10 mg [n = 49]) and placebo (n = 45) were eligible for the efficacy anal. Mean daily off time from baseline to week 12 was reduced vs. placebo in patients on 5 mg preladenant (difference -1.0 h, 95% CI -2.1 to 0.0; p = 0.0486) and 10 mg preladenant (-1.2 h, -2.2 to -0.2; p = 0.019). Changes in mean daily off time vs. placebo were not significant for 1 mg preladenant (0.2 h, -0.9 to 1.2; p = 0.753) or 2 mg preladenant (-0.7 h, -1.7 to 0.3; p = 0.162). The most common adverse events in the combined preladenant group vs. placebo were worsening of Parkinson’s disease (22 [11%] vs 4 [9%]), somnolence (20 [10%] vs 3 [6%]), dyskinesia (18 [9%] vs 6 [13%]), nausea (17 [9%] vs 5 [11%]), constipation (15 [8%] vs 1 [2%]), and insomnia (15 [8%] vs 4 [9%]). 5 and 10 mg preladenant twice daily might be clin. useful to reduce off time in patients with Parkinson’s disease and motor fluctuations. Funding: Schering-Plough, a subsidiary of Merck.

Lancet Neurology published new progress about 377727-87-2. 377727-87-2 belongs to triazoles, auxiliary class GPCR/G Protein,Adenosine Receptor, name is 2-(Furan-2-yl)-7-(2-(4-(4-(2-methoxyethoxy)phenyl)piperazin-1-yl)ethyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine, and the molecular formula is C25H29N9O3, Application In Synthesis of 377727-87-2.

Referemce:
https://en.wikipedia.org/wiki/1,2,3-Triazole,
Triazoles – an overview | ScienceDirect Topics

Zhou, Ru-Shuang published the artcileC-H Amination of Nitro Azaheterocyclic Compounds by Vicarious Nucleophilic Substitution, Recommanded Product: 4-Nitro-2H-1,2,3-triazole, the publication is Synlett (2022), 33(1), 88-92, database is CAplus.

Various nitro azaheterocyclic compounds were subjected to C-H amination by vicarious nucleophilic substitution with 4H-1,2,4-triazol-4-amine (ATA). The aminated products were characterized by NMR, mass spectroscopy, and single-crystal X-ray diffraction analyses. The substrates examined gave moderate to excellent yields (30-88%) and showed good regioselectivities. This protocol offers the advantages of mild conditions, a short reaction time (2-4 h), and an inexpensive, com. available, and less-toxic amination reagent; moreover, no addnl. catalyst or reagent is needed. A possible reaction mechanism is discussed.

Synlett published new progress about 84406-63-3. 84406-63-3 belongs to triazoles, auxiliary class Triazole,Nitro Compound, name is 4-Nitro-2H-1,2,3-triazole, and the molecular formula is C15H14O, Recommanded Product: 4-Nitro-2H-1,2,3-triazole.

Referemce:
https://en.wikipedia.org/wiki/1,2,3-Triazole,
Triazoles – an overview | ScienceDirect Topics

Fray, M. Jonathan published the artcileStructure-Activity Relationships of 1,4-Dihydro-(1H,4H)-quinoxaline-2,3-diones as N-Methyl-D-aspartate (Glycine Site) Receptor Antagonists. 1. Heterocyclic Substituted 5-Alkyl Derivatives, Name: 4H-1,2,4-Triazole, the publication is Journal of Medicinal Chemistry (2001), 44(12), 1951-1962, database is CAplus and MEDLINE.

A series of 6,7-dichloro-1,4-dihydro-(1H,4H)-quinoxaline-2,3-diones were prepared in which the 5-position substituent was a heterocyclylmethyl or 1-(heterocyclyl)-1-Pr group. Structure-activity relationships were evaluated where binding affinity for the glycine site of the N-methyl-D-aspartate (NMDA) receptor was measured using the specific radioligand [³H]-L-689,560, and functional antagonism was demonstrated by inhibition of NMDA-induced depolarizations of rat cortical wedges. The ability to prevent NMDA-induced hyperlocomotion in mice in vivo was measured for selected compounds Binding affinity increased significantly if the heterocyclic group, e.g. 1,2,3-triazol-1-yl could participate in accepting a hydrogen bond from the receptor. It was difficult to obtain compounds with adequate aqueous solubility and strategies to improve it were investigated. The most potent compound in this series, 6,7-dichloro-5-[1-(1,2,4-triazol-4-yl)propyl]-1,4-dihydro-(1H,4H)-quinoxaline-2,3-dione (I) (binding IC₅₀ = 2.6 nM; cortical wedge EC₅₀ = 90 nM), inhibited NMDA-induced hyperlocomotion in mice (6/9 protected at 20 mg/kg iv). Pharmacokinetic parameters, including extent of brain penetration, for I and 6,7-dichloro-5-[(1-propyl-4-imidazolyl)methyl]-1,4-dihydro-(1H,4H)-quinoxaline-2,3-dione are reported.

Journal of Medicinal Chemistry published new progress about 63598-71-0. 63598-71-0 belongs to triazoles, auxiliary class Triazole, name is 4H-1,2,4-Triazole, and the molecular formula is C2H3N3, Name: 4H-1,2,4-Triazole.

Referemce:
https://en.wikipedia.org/wiki/1,2,3-Triazole,
Triazoles – an overview | ScienceDirect Topics

Jones, Carrie K. published the artcileThe metabotropic glutamate receptor 4-positive allosteric modulator VU0364770 produces efficacy alone and in combination with L-DOPA or an adenosine 2A antagonist in preclinical rodent models of Parkinson’s disease, Product Details of C25H29N9O3, the publication is Journal of Pharmacology and Experimental Therapeutics (2012), 340(2), 404-421, database is CAplus and MEDLINE.

Parkinson’s disease (PD) is a debilitating neurodegenerative disorder associated with severe motor impairments caused by the loss of dopaminergic innervation of the striatum. Previous studies have demonstrated that pos. allosteric modulators (PAMs) of metabotropic glutamate receptor 4 (mGlu₄), including N-phenyl-7-(hydroxyimino)cyclopropa[b]chromen-1a-carboxamide, can produce antiparkinsonian-like effects in preclin. models of PD. However, these early mGlu₄ PAMs exhibited unsuitable physiochem. properties for systemic dosing, requiring intracerebroventricular administration and limiting their broader utility as in vivo tools to further understand the role of mGlu₄ in the modulation of basal ganglia function relevant to PD. In the present study, we describe the pharmacol. characterization of a systemically active mGlu₄ PAM, N-(3-chlorophenyl)picolinamide (VU0364770), in several rodent PD models. VU0364770 showed efficacy alone or when administered in combination with L-DOPA or an adenosine 2A (A_2A) receptor antagonist currently in clin. development (preladenant). When administered alone, VU0364770 exhibited efficacy in reversing haloperidol-induced catalepsy, forelimb asymmetry-induced by unilateral 6-hydroxydopamine (6-OHDA) lesions of the median forebrain bundle, and attentional deficits induced by bilateral 6-OHDA nigrostriatal lesions in rats. In addition, VU0364770 enhanced the efficacy of preladenant to reverse haloperidol-induced catalepsy when given in combination. The effects of VU0364770 to reverse forelimb asymmetry were also potentiated when the compound was coadministered with an inactive dose of L-DOPA, suggesting that mGlu₄ PAMs may provide L-DOPA-sparing activity. The present findings provide exciting support for the potential role of selective mGlu₄ PAMs as a novel approach for the symptomatic treatment of PD and a possible augmentation strategy with either L-DOPA or A_2A antagonists.

Journal of Pharmacology and Experimental Therapeutics published new progress about 377727-87-2. 377727-87-2 belongs to triazoles, auxiliary class GPCR/G Protein,Adenosine Receptor, name is 2-(Furan-2-yl)-7-(2-(4-(4-(2-methoxyethoxy)phenyl)piperazin-1-yl)ethyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine, and the molecular formula is C25H29N9O3, Product Details of C25H29N9O3.

Referemce:
https://en.wikipedia.org/wiki/1,2,3-Triazole,
Triazoles – an overview | ScienceDirect Topics

Ostrovskii, V. A. published the artcileStudy of five-membered nitrogen-containing heterocycles by quantum-chemical methods. II. Structure and aromaticity of azoles, Recommanded Product: 4H-1,2,4-Triazole, the publication is Zhurnal Organicheskoi Khimii (1995), 31(9), 1422-1431, database is CAplus.

The MNDO method was used to study the electronic and geometric structure of 5-membered heterocycles, their anions, and their protonated forms. Reactivities, acidities, and basicities were related to at. charges. In contrast to the anions, the neutral and protonated forms exhibit relatively low aromaticity.

Zhurnal Organicheskoi Khimii published new progress about 63598-71-0. 63598-71-0 belongs to triazoles, auxiliary class Triazole, name is 4H-1,2,4-Triazole, and the molecular formula is C2H3N3, Recommanded Product: 4H-1,2,4-Triazole.

Referemce:
https://en.wikipedia.org/wiki/1,2,3-Triazole,
Triazoles – an overview | ScienceDirect Topics

Walker, Donald G. published the artcileUse of bistrimethylsilylated intermediates in the preparation of semisynthetic 7-amino-3-substituted cephems. Expedient syntheses of a new 3-[(1-methyl-1-pyrrolidinio)methyl]cephalosporin, Quality Control of 59032-27-8, the publication is Journal of Organic Chemistry (1988), 53(5), 983-91, database is CAplus.

Several one-pot methods are presented for conversion of 7-aminocephalosporanic acid (I) to 7-amino-3-(ammoniomethyl)-II (R = N-methylpyrrolidine, pyridine, cyclopenta[b]pyridine) or 7-amino-3-[[(heteroaroyl)thio]methyl]cephalosporin derivatives III (R¹ = 1-methyl-5-tetrazolyl, 5-methyl-1,3,4-thiadiazol-2-yl, 1,2,3-triazol-4-yl, 1-carboxymethyltetrazol-5-yl) via bistrimethylsilylated intermediates. For example, bistrimethylsilylation of I in Freon TF using (Me₃Si)₂NH and 3 mol % Me₃SiI, followed by treatment with 1.15 equivalent of Me₃SiI and subsequent reactions with the amines or thiols, led to II and III in good yields. The novel reaction of the bistrimethylsilylated derivative of I with amine-Me₃SiI adducts in Freon TF at 35° provided an alternative approach to II. The solvent dependence of Δ³/Δ² isomer ratios in the preparation of II (R = N-methylpyrrolidine) is presented.

Journal of Organic Chemistry published new progress about 59032-27-8. 59032-27-8 belongs to triazoles, auxiliary class Triazoles, name is Sodium 1,2,3-triazole-5-thiolate, and the molecular formula is C8H6ClNO, Quality Control of 59032-27-8.

Referemce:
https://en.wikipedia.org/wiki/1,2,3-Triazole,
Triazoles – an overview | ScienceDirect Topics

Smiglak, Marcin published the artcileDirect, atom efficient, and halide-free syntheses of azolium azolate energetic ionic liquids and their eutectic mixtures, and method for determining eutectic composition, Recommanded Product: 5-Nitro-1H-1,2,3-triazole, the publication is Chemistry – A European Journal (2008), 14(36), 11314-11319, database is CAplus and MEDLINE.

The author proposed a successful halide-free, efficient syntheses of azolium azolates by reaction of 1,3-dimethylimidazolium-2-carboxylate with neutral azoles (by a one-pot synthesis with an easy to remove byproduct, namely CO₂ gas). A facile, low sample demand method was developed for ready determination of the eutectic point compositions of mixtures of these salts. New synthetic techniques were applied to direct preparation of the eutectic mixtures

Chemistry – A European Journal published new progress about 14544-45-7. 14544-45-7 belongs to triazoles, auxiliary class Triazoles, name is 5-Nitro-1H-1,2,3-triazole, and the molecular formula is C6H12O2, Recommanded Product: 5-Nitro-1H-1,2,3-triazole.

Referemce:
https://en.wikipedia.org/wiki/1,2,3-Triazole,
Triazoles – an overview | ScienceDirect Topics

Licht, H. H. published the artcileNitrotriazoles. Chemical structure and explosive properties, Application In Synthesis of 84406-63-3, the publication is International Annual Conference of ICT (1998), 47.1-47.15, database is CAplus.

The structure of 19 nitrotriazoles was studied (7 compounds were prepared for the 1st time) to determine the influence of chem. structures on the explosive properties. The anal. procedures are very expensive because of tautomerism and isomerism. The determination of explosive properties yielded striking differences. There were insensitive high explosives and compounds which proved to be primary explosives.

International Annual Conference of ICT published new progress about 84406-63-3. 84406-63-3 belongs to triazoles, auxiliary class Triazole,Nitro Compound, name is 4-Nitro-2H-1,2,3-triazole, and the molecular formula is C2H2N4O2, Application In Synthesis of 84406-63-3.

Referemce:
https://en.wikipedia.org/wiki/1,2,3-Triazole,
Triazoles – an overview | ScienceDirect Topics